Philogen

Philogen

Italy - Monteriggioni
Biotechnology

Focus: Small Molecules, Biologics, ADCs

Philogen is a life sciences company focused on Small Molecules, Biologics, ADCs.

OncologyUnknownImmunology
Funding Stage
PUBLIC
Open Jobs
12

Pipeline & Clinical Trials

Phase 1
Clinical Trials (1)
NCT04471987Safety and Early Signs of Efficacy of IL12-L19L19.
Phase 1
Clinical Trials (1)
NCT02076620L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours
Phase 1
Clinical Trials (1)
NCT02076659Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients
Phase 1
Clinical Trials (1)
NCT02957032A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Phase 1
Clinical Trials (1)
NCT01198522Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients
Phase 1
Clinical Trials (1)
NCT07245992A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis
Phase 1
Phase 1
Clinical Trials (1)
NCT04032964Dose Finding Study of L19TNF and Doxorubicin in Patients With STS
Phase 1
Clinical Trials (1)
NCT05622175Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment
Phase 1
131I-L19SIP Radioimmunotherapy
Non Small Cell Lung Cancer
Phase 1
Clinical Trials (1)
NCT01124812131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC)
Phase 1
[68Ga]Ga-OncoFAP administration
Breast Cancer
Phase 1
Clinical Trials (1)
NCT05784597A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors
Phase 1
Onfekafusp alfa
Glioblastoma
Phase 1
Clinical Trials (1)
NCT05304663Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression
Phase 1
Isolated inferior limb perfusion
Patients With Intransit Stage III/IV Melanoma
Phase 1
Clinical Trials (1)
NCT01213732Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma
Phase 1
[177Lu]Lu-OncoFAP-23
FAP
Phase 1
Clinical Trials (1)
NCT06640413A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors
Phase 1
[68Ga]Ga-OncoACP3
Prostate Cancer
Phase 1
Clinical Trials (1)
NCT06840535A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer
Phase 1
Clinical Trials (1)
NCT06840548A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer
Phase 1
Phase 1/2
Clinical Trials (1)
NCT02076646A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT03779230Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT04573192A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT01253837L19TNFα in Patients With Advanced Solid Tumors
Phase 1/2
Clinical Trials (1)
NCT02957019A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Phase 1/2
F16IL2 in combination with doxorubicin
Advanced Solid Tumor
Phase 1/2
Clinical Trials (1)
NCT01131364Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients
Phase 1/2
131I-L19SIP Radioimmunotherapy
Patients With Cancer
Phase 1/2
Clinical Trials (1)
NCT01242943Radioimmunotherapy With 131I-L19SIP in Patients With Cancer
Phase 1/2
Clinical Trials (1)
NCT05468294F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer
Phase 1/2
131I-F16SIP Radioimmunotherapy
Cancer
Phase 1/2
Clinical Trials (1)
NCT01240720A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT01058538A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours
Phase 1/2
F16IL2 in combination with paclitaxel
Solid Tumor
Phase 1/2
Clinical Trials (1)
NCT01134250Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients
Phase 1/2
Onfekafusp alfa
Glioblastoma
Phase 1/2
Clinical Trials (1)
NCT04443010Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
Phase 1/2
Clinical Trials (1)
NCT02270632A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTX
Phase 2
Doxorubicin
Leiomyosarcoma
Phase 2
Clinical Trials (1)
NCT03420014Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)
Phase 2
Arm A: F16IL2 in combination with paclitaxel
Merkel Cell Carcinoma
Phase 2
131I-L19SIP Radioimmunotherapy
Brain Metastases From Solid Tumors
Phase 2
Clinical Trials (1)
NCT01125085131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors
Phase 2
Clinical Trials (1)
NCT07227350L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Phase 2
Phase 2
Clinical Trials (1)
NCT06336291A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
Phase 2
Phase 2
Clinical Trials (1)
NCT05329792L19IL2/L19TNF in Skin Cancer Patients
Phase 2
L19IL2 +L19TNF
Carcinoma, Basal Cell
Phase 2
Clinical Trials (1)
NCT04362722Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients
Phase 2
Phase 2
Clinical Trials (1)
NCT02076633Intratumoral Administration of L19IL2/L19TNF
Phase 2
Intratumoral injections of L19IL2
Malignant Melanoma
Phase 2
Clinical Trials (1)
NCT01253096Intratumoral Application of L19IL2 in Patients With Malignant Melanoma
Phase 2
L19TNF
Glioma
Phase 2
Clinical Trials (1)
NCT07120984A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma
Phase 2
Phase 2
Clinical Trials (1)
NCT07227870L19IL2/TNF in Patients With Basal Cell Carcinoma
Phase 2
Phase 2
Clinical Trials (1)
NCT04733183Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
Phase 2
Clinical Trials (1)
NCT07228442L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
Phase 2
Arm 1: L19IL2 + Dacarbazine
Metastatic Melanoma
Phase 2
Clinical Trials (1)
NCT01055522Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
Phase 2
Phase 3
Clinical Trials (1)
NCT03567889Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
Phase 3
Onfekafusp alfa
Soft Tissue Sarcoma
Phase 3
Clinical Trials (1)
NCT04650984A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Phase 3
L19IL2 + L19TNF
Malignant Melanoma
Phase 3
Clinical Trials (1)
NCT02938299Neoadjuvant L19IL2/L19TNF- Pivotal Study
Phase 3

Open Jobs (12)

Interview Prep Quick Facts
Founded: 1996
Portfolio: 45 clinical trials
Top TAs: Oncology, Immunology
Open Roles: 12 active jobs
Therapeutic Area Focus
Oncology
40 pipeline
Immunology
4 pipeline
Marketed
Pipeline